BackCatalyst Pharmaceuticals Overview
Catalyst Pharmaceuticals Inc

Catalyst Pharmaceuticals Target Price

Analysts' average 12-month price target for Catalyst Pharmaceuticals is $32.

Get informed when a big investor buys or sells

+ Follow

Share Price

$31.49

Average Target Price

$31.750.8% upside

2 analysts in the last 4 months

High: $32 | Low: $31.5

Analyst Recommendations

No recommendations in the last 4 months.

Revenue & Income Forecast

Analysts' Target Prices

DateAnalystPrice TargetCurrent Upside/Downside
2026-05-28H.C. Wainwright$31.50% upsideOpen
2026-05-07Stephens$321.6% upsideOpen
2025-11-07OppenheimerLeland Gershell$334.8% upsideOpen
2025-03-03Robert W. Baird$321.6% upsideOpen
2025-02-04Robert W. BairdJoel Beatty$2811.1% downsideOpen
2025-01-10H.C. WainwrightAndrew Fein$3511.1% upsideOpen
2022-12-21Truist Financial$1842.8% downsideOpen
2022-12-21H.C. Wainwright$2423.8% downsideOpen
2022-12-19Piper SandlerJoseph Catanzaro$2036.5% downsideOpen
2022-08-24Roth CapitalScott Henry$15.550.8% downsideOpen
2022-08-11Truist Financial$1746% downsideOpen
2022-08-11H.C. Wainwright$1842.8% downsideOpen

Catalyst Pharmaceuticals (CPRX) FAQ

Catalyst Pharmaceuticals posts a target price of $32. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

A target price of $32 for CPRX means covering analysts, on average, see the stock 0.8% upside of $31.49 over about 12 months. Dig into who set the high and low targets and how recently they updated — freshness matters as much as the average itself.

Context for CPRX's target price usually means three checks: (1) trend versus prior periods, (2) level versus peers, and (3) consistency with growth and profitability. This page covers the first two; Catalyst Pharmaceuticals's other metric pages and overview cover the third.

Judging Catalyst Pharmaceuticals against Healthcare peers is usually better than using a market-wide rule of thumb. Business models inside Healthcare are more comparable, which makes gaps in target price easier to interpret. Start with $32 here, then scan peer and history charts to see if the gap is persistent.